Search

Displaying results 2711 - 2720 of 10000 in total
  1. Drug

    Taliglucerase alfa

    go.drugbank.com/drugs/DB08876
    Approved

    It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease. … Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase.

    Products: ELELYSO 200 U İNFÜZYONLUK SOLÜSYON İÇİN LİYOFİLİZE TOZ, 1 ADET
  2. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell … Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [Curcuma xanthorrhiza oil].

    Categories: Compounds used in a research, industrial, or household setting, Analgesics, Non-Narcotic
  3. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

    Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-
  4. Drug

    Mercaptopurine

    go.drugbank.com/drugs/DB01033
    ApprovedInvestigational

    It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. … An antimetabolite antineoplastic agent with immunosuppressant properties.

    Categories: Drugs for Obstructive Airway Diseases
  5. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. … It was granted approval by FDA in August 2017 under the market name Kymriah.

  6. Drug

    XPro1595

    go.drugbank.com/drugs/DB16454
    Investigational

    XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.

    Synonyms: HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA.Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. … [A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]

    Categories: Antihypertensive Agents Indicated for HypertensionProducts: CORETEL-N
  8. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body.

    Categories: Antihistamines for Systemic Use
  9. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]

  10. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization … [A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g.

    Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide